252 related articles for article (PubMed ID: 16918408)
1. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting.
Meyer A; Auernheimer J; Modlinger A; Kessler H
Curr Pharm Des; 2006; 12(22):2723-47. PubMed ID: 16918408
[TBL] [Abstract][Full Text] [Related]
2. Integrins in drug targeting-RGD templates in toxins.
Lu X; Lu D; Scully MF; Kakkar VV
Curr Pharm Des; 2006; 12(22):2749-69. PubMed ID: 16918409
[TBL] [Abstract][Full Text] [Related]
3. Biological Relevance of RGD-Integrin Subtype-Specific Ligands in Cancer.
Sani S; Messe M; Fuchs Q; Pierrevelcin M; Laquerriere P; Entz-Werle N; Reita D; Etienne-Selloum N; Bruban V; Choulier L; Martin S; Dontenwill M
Chembiochem; 2021 Apr; 22(7):1151-1160. PubMed ID: 33140906
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in biomedical applications of RGD-based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review.
Alipour M; Baneshi M; Hosseinkhani S; Mahmoudi R; Jabari Arabzadeh A; Akrami M; Mehrzad J; Bardania H
J Biomed Mater Res A; 2020 Apr; 108(4):839-850. PubMed ID: 31854488
[TBL] [Abstract][Full Text] [Related]
5. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
6. RGD and other recognition sequences for integrins.
Ruoslahti E
Annu Rev Cell Dev Biol; 1996; 12():697-715. PubMed ID: 8970741
[TBL] [Abstract][Full Text] [Related]
7. Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles.
Arosio D; Casagrande C; Manzoni L
Curr Med Chem; 2012; 19(19):3128-51. PubMed ID: 22612699
[TBL] [Abstract][Full Text] [Related]
8. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis.
Dresner-Pollak R; Rosenblatt M
J Cell Biochem; 1994 Nov; 56(3):323-30. PubMed ID: 7876325
[TBL] [Abstract][Full Text] [Related]
9. Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.
Zheng Y; Leftheris K
J Med Chem; 2020 Jun; 63(11):5675-5696. PubMed ID: 31999923
[TBL] [Abstract][Full Text] [Related]
10. Modulating angiogenesis with integrin-targeted nanomedicines.
Duro-Castano A; Gallon E; Decker C; Vicent MJ
Adv Drug Deliv Rev; 2017 Sep; 119():101-119. PubMed ID: 28502767
[TBL] [Abstract][Full Text] [Related]
11. RGD-based Therapy: Principles of Selectivity.
Rubtsov MA; Syrkina MS; Aliev G
Curr Pharm Des; 2016; 22(7):932-52. PubMed ID: 26648463
[TBL] [Abstract][Full Text] [Related]
12. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
Sheldrake HM; Patterson LH
J Med Chem; 2014 Aug; 57(15):6301-15. PubMed ID: 24568695
[TBL] [Abstract][Full Text] [Related]
13. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
14. Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets.
Sun CC; Qu XJ; Gao ZH
Am J Ther; 2016; 23(1):e198-207. PubMed ID: 24621642
[TBL] [Abstract][Full Text] [Related]
15. Tumor targeting by surface-modified protein microspheres.
Toublan FJ; Boppart S; Suslick KS
J Am Chem Soc; 2006 Mar; 128(11):3472-3. PubMed ID: 16536492
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of beta-amino acid-containing integrin antagonists.
Scarborough RM
Curr Med Chem; 1999 Oct; 6(10):971-81. PubMed ID: 10519908
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging of avb3 expression in cancer patients.
Gaertner FC; Schwaiger M; Beer AJ
Q J Nucl Med Mol Imaging; 2010 Jun; ():. PubMed ID: 20559198
[TBL] [Abstract][Full Text] [Related]
18. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Rüegg C; Dormond O; Mariotti A
Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
[TBL] [Abstract][Full Text] [Related]
19. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates.
Shukla R; Thomas TP; Peters J; Kotlyar A; Myc A; Baker JR
Chem Commun (Camb); 2005 Dec; (46):5739-41. PubMed ID: 16307130
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand.
Hall ER; Bibby LI; Slack RJ
Biochem Pharmacol; 2016 Oct; 117():88-96. PubMed ID: 27501918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
